HTB

Side effects

Bone problems raised in several UK studies

New-fill used to treat lipoatropy in feet

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

Case report of efavirenz-associated nephrolithiasis

Yellow card reporting scheme for doctors and patients in the UK

30 cases of atazanavir-related kidney stones reported

Tenofovir and indinavir associated with increased risk of chronic renal failure in EuroSIDA study

Growth hormone release factor (TH9507) reduces central fat adiposity

Further insight into risk and management of cardiovascular disease (CVD) from D:A:D cohort: no additional benefit of metabolic syndrome diagnosis; new HIV-specific CVD risk equations; increasing uptake of lipid lowering drugs but low smoking cessation

d4T associated with significantly increased risk of type-2 diabetes mellitus

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

The role of the metabolic syndrome in HIV

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin

Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions

Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa

D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy

Interventions for the management of lipodystrophy and metabolic complications

Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand

Factors associated with sexual dysfunction in HIV patients

African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects

Predictors of insulin resistance in first year of therapy

Monitoring side effects in resource limited countries

Uridine supplement reverses thymidine-induced lipoatrophy

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

Niacin has beneficial effect on lipids but no reduction in abdominal fat

Gluteal implants used to replace lost buttock fat

Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy

EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients

EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection

Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin

Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age

Omega-3 supplement effective to reduce triglycerides

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

rHGH reduces central fat accumulation in adolescent lipodystrophy

Endothelial dysfunction similar in ARV-experienced and -naive patients

Pravastatin improves lipid profiles but not endothelial function

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

Improvement of lipids following switch to tenofovir

Restorative treatments for HIV-associated lipoatrophy

Side effects update: hypersensitivity, heart, bones

Vancouver researchers urge caution with combinations of lipid drugs

Three-year renal safety with tenofovir; cystatin may be a useful marker

Efficacy of acetyl-L-carnitine for antiretroviral toxic neuropathy

Oral uridine to treat mitochondrial toxicity

Phase II results show ThGRF could be safe, effective treatment for lipodystrophy, says company

Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir

Diabetes and HIV and HCV; aging/HIV and diabetes

Eating grapefruit triggers statin-related rhabdomyolysis

FDA panel recommends approval of New-Fill

Lipodystrophy regresses in three patients switched to atazanavir

Race affects absorption and clearance of efavirenz

Update on peripheral neuropathy in HIV-infection

Smoking marijuana provides analgesic effect on HIV neuropathy

Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure

Low-dose rHGH maintains reductions in abdominal fat for 60 weeks

Rosiglitazone shows no benefit for lipoatrophy

Importance of dietary management in treating lipid disorders: soy diets may offer comparable effect as statins

Lower doses of d4T produce similar efficacy and reduced side effects

Post navigation